Divi's Labs Q1 Review — Motilal Oswal Retains 'Neutral' Stance, Says Current Valuation Leaves Limited Upside
Peptide is expected to be the next breakthrough opportunity for Divi's, adds Motilal Oswal
(Representative image. Photo source: Unsplash)
Divi’s Laboratories posted lower-than-expected financial performance in Q1 FY26. Revenue/Ebitda/PAT came in 5%/14%/18% below our estimates, affected by lower traction in the generics segment and increased opex. Having said this, Q1 FY26 was the seventh consecutive quarter of robust YoY growth in earnings.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We cut our earnings estimates of Divi's Laboratories Ltd. by 8%/6% for FY26/FY27, factoring in-
the current pricing pressure in the generics segment,
incremental opex related to new projects, and
revenue being back-ended.
We value Divi's at 54x 12 months forward earnings to arrive at a target price of Rs 6,320.
We estimate 20% earnings CAGR over FY25-27 on the back of improved business prospects in the CS segment as certain contracts are currently undergoing pilot study/qualification and subsequently expected to scale up to the commercial level.
Notably, peptide is expected to be the next breakthrough opportunity for Divi's.
However, the current valuation leaves limited upside; hence, we maintain Neutral stance on the stock.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
